Hitachi Chemical Advanced Therapeutics Solutions Increases Stake In Counter-Flow Centrifugation

Centrifuge tubes. Source: LJNovaScotia, no changes made, CC0 Creative Commons.
Advertisement img

Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms including cell therapies targeting select cardiovascular indications and autoimmune diseases.

Invetech Pty Ltd., is a full-service provider of product design, instrument development and contract manufacturing with a focus on healthcare markets.

Hitachi Chemical Advanced Therapeutics Solutions LLC (“HCATS”) is a global Contract Development and Manufacturing Organization (“CDMO”) that formed out of the acquisition of PCT Cell Therapy Services, LLC. from Caladrius Biosciences, Inc. The business unit focuses on cell therapy and regenerative medicine.

Featured Partners

Caladrius Biosciences has sold for $2.5 million its ownership interest in a development-stage, fully enclosed, automated, programmable counter-flow centrifugation (“CFC”) system for use in cell therapy manufacturing to HCATS.

A fully enclosed manufacturing environment is the vision behind the innovation of the instrument, where cell processing is robust, automated and reproducible with associated cost reductions. Cell therapy developers can wash and concentrate cells using the CFC system.

The CFC system was specifically designed for compliance with Good Manufacturing Practice (“GMP”) and to be a key element in the commercial manufacture of cell therapies. The system is compatible with multiple stages of research, development, and production to achieve concentration, cell washing, media exchange, particle sedimentation, and short incubation.

“We are particularly pleased to have sold our rights to the CFC system to the team we have worked so closely with at HCATS, knowing that it is in the hands of scientists, engineers and business people with the expertise to advance this technology, in partnership with Invetech Pty Ltd., and to bring it to market with the highest probability of success,” … “Caladrius’ focus is solely on therapeutic product development, and the sale of this non-core asset provides non-dilutive funds to further support our key strategic interests.” – David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius Biosciences.